[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 25, 2007

Hypertrophic Cardiomyopathy, Sudden Death, and Implantable Cardiac Defibrillators: How Low the Bar?

Author Affiliations

Author Affiliations: Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota.

JAMA. 2007;298(4):452-454. doi:10.1001/jama.298.4.452

Hypertrophic cardiomyopathy (HCM) is a relatively common disorder (occurring in approximately 1 in 500 adults in the general population)1,2 and has the widely recognized clinical findings of massive myocardial hypertrophy and dynamic left ventricular outflow tract obstruction. Once thought to be a disease of unknown etiology, HCM is now recognized as a genetic disorder often caused by a mutation in at least 1 of 12 genes that encode the proteins of the cardiac sarcomere.3